Optimising the prevention and management of HIV associated cryptococcal meningitis

In summary

Cryptococcal disease is a leading cause of meningitis in HIV-infected adults, adolescents, and children in sub-Saharan Africa. Adoption of amphotericin B-based treatments and improved fluconazole dosing has reduced 10-week mortality from over 50% to 25-35%.

These advances have been incorporated into regional and international guidelines since 2007, with updates in 2011 and 2013.

What did we explore and how?

The City St George’s team assessed antifungal therapies and advocated for cost-effective treatment strategies.

Their work prompted pharmaceutical company Bristol Myers Squibb to reduce the price of amphotericin B in South Africa by 80% (from 146 to 26 ZAR/50mg vial).

This price reduction increased amphotericin B use for induction therapy from 34% of patients in 2005 to 83% in 2010.

In line with international recommendations, the team supported increasing the standard fluconazole dose to 1200 mg/d across many sub-Saharan African countries.

Following this evidence, the South African Department of Health began a phased rollout of cryptococcal meningitis screening and pre-emptive treatment for newly diagnosed HIV patients.

This strategy, endorsed by WHO guidelines in 2011 and updated Southern African Clinicians Society guidelines in 2013, is now routine in South Africa’s Western Cape and Gauteng provinces and being adopted in Uganda, Kenya, Zambia, and Tanzania.

Benefits and influence of this research

Implementation of screening and pre-emptive treatment has significantly lowered cryptococcal meningitis cases presenting after HIV diagnosis and antiretroviral therapy initiation.

A cost-effectiveness analysis showed that screening saves both lives and healthcare costs, making it the optimal standard of care.

The research has shaped international and regional clinical guidelines, influencing health policy and clinical practice across sub-Saharan Africa and improving outcomes for people living with HIV.